The
rising prevalence of cancer, rapid growth in geriatric population, and
increasing number of emergency surgeries are some of the major factors driving
the growth of the US general anesthesia drugs.
The
US general anesthesia
drugs market size is projected to reach USD 2.4 billion by
2025 from USD 2.0 billion in 2020, at a CAGR of 3.4% during the forecast
period.
Market
Segmentation: -
Intravenous anesthesia drugs accounted for the largest share in the US
general anesthesia drugs market in 2019.
Based on the route
of administration, US general anesthesia drugs market is categorized into
inhalational anesthesia drugs and intravenous anesthesia drugs. The inhalational
anesthesia drugs is further categorized into sevoflurane, desflurane,
isoflurane and nitrous oxide. Similarly, intravenous anesthesia drugs are
further categorized into propofol, benzodiazepines, ketamine, methohexital
sodium and others intravenous general anesthesia drugs. The intravenous segment
accounted for the largest share of the market. General intravenous
anesthesia drugs are less expensive and do not require expensive machines for
administration which contributes to the high market share of the segment.
Hospitals accounted for the largest share in the US general anesthesia
drugs market in 2019
Based on end user,
the US general anesthesia drugs market has been segmented into hospitals and
ambulatory surgery centers. The hospitals segment accounted for the largest
share of the US general anesthesia drugs market in 2019. The massive patient
footfall in hospitals and the increasing number of surgeries performed in these
facilities are the factors responsible for the largest share of the segment.
Key Market Players: -
The US general anesthesia
drugs market is dominated by a few established players such as Baxter
International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US),
Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA
(Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel),
Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc
(US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead
Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany),
Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex
(Canada) among others.